Raynaud's Treatment Study (RTS)
|Cardiovascular Diseases Heart Diseases Raynaud's Disease Vascular Diseases||Drug: nifedipine Behavioral: biofeedback (psychology) Procedure: electromyography||Phase 3|
|Study Design:||Allocation: Randomized
Primary Purpose: Treatment
|Study Start Date:||September 1992|
|Estimated Study Completion Date:||June 1998|
Primary Raynaud's phenomenon is a peripheral vascular disorder resulting in vasospastic attacks provoked by cold and/or emotional stress. Attacks most often occur in the fingers, but may occur in other extremities as well.
Randomized. Patients were assigned to one of four treatment groups: slow release Nifedipine, a calcium channel blocker; pill placebo; temperature biofeedback; or electromyograph biofeedback from the frontalis muscle. The primary endpoint was reduction in number of vasospastic attacks. Other endpoints included: other measures of Raynaud's attacks including frequency, severity, duration, response to laboratory-based cold challenge, and quality of life.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000530
|OverallOfficial:||Bruce Thompson||Clinical Trials & Surveys Corp (C-TASC)|